{"entity":{"id":"obrixtamig","kind":"drug","name":"Obrixtamig","aka":["BI 764532","BI-764532"],"tldr":"Obrixtamig is an antibody with two arms: one grabs DLL3, a protein on the surface of most neuroendocrine carcinomas, and the other grabs a T cell, pulling the killer cell onto the cancer. It is in a phase 3 trial for neuroendocrine carcinomas outside the lung.","summary":"Obrixtamig (BI 764532) is Boehringer Ingelheim's DLL3-directed T-cell engager, a class established by tarlatamab in small-cell lung cancer. DLL3 is expressed on the surface of most small-cell lung cancers and extrapulmonary neuroendocrine carcinomas but almost no normal adult tissue. It is given intravenously with step-up dosing to limit cytokine release syndrome.\n\nThe phase 2 DAREON-5 trial reported responses in DLL3-positive small-cell lung cancer and extrapulmonary neuroendocrine carcinoma, and the phase 3 DAREON-NEC-1 trial is testing obrixtamig with carboplatin and etoposide first line in DLL3-positive extrapulmonary neuroendocrine carcinoma, the first phase 3 dedicated to that disease. The extrapulmonary neuroendocrine carcinoma page names it with peluntamig and ZG006 among the DLL3 engagers in trials.","status":"phase-3","asOf":"2026-09-17","links":[],"tags":["subtype-drugs-wave"],"related":["tarlatamab","peluntamig","zg006"],"cancers":["extrapulmonary-nec"],"sections":[],"technologies":["t-cell-engager","bispecific-antibody"],"targets":["dll3","cd3"],"drugs":[],"companies":["boehringer-ingelheim"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"code":"BI 764532","modality":"DLL3 x CD3 bispecific T-cell engager","mechanism":"One arm binds delta-like ligand 3 on neuroendocrine carcinoma cells and the other binds CD3 on T cells, forcing an immune synapse that makes the T cell kill the tumour cell.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/obrixtamig/","neighbours":{"drug":[{"id":"peluntamig","kind":"drug","name":"Peluntamig","route":"/drugs/peluntamig/"},{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/"},{"id":"zg006","kind":"drug","name":"ZG006","route":"/drugs/zg006/"}],"cancer":[{"id":"extrapulmonary-nec","kind":"cancer","name":"Extrapulmonary neuroendocrine carcinoma","route":"/cancers/extrapulmonary-nec/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"},{"id":"dll3","kind":"target","name":"DLL3","route":"/targets/dll3/"}],"company":[{"id":"boehringer-ingelheim","kind":"company","name":"Boehringer Ingelheim","route":"/companies/boehringer-ingelheim/"}]}}